支气管动脉化学栓塞用于治疗耐火性中枢肺癌的治疗,使用阿特莱克塔西斯
Yujin Liu1, Xiumei Zhang2, Fenxiang Zhang1
1Department of Interventional Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Frontiers in oncology
|June 27, 2024
概括
支气管动脉化学栓塞 (BACE) 提供了一种安全的选择,用于治疗中枢肺癌,改善生活质量和瘤控制. 这种干预性放射技术在治疗耐火病例方面显示出有希望的结果.
科学领域:
- 干预性放射学 干预性放射学
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
背景情况:
- 耐火性中枢肺癌与阿特莱克塔斯 (atelectasis) 存在重大管理挑战.
- 现有的治疗方法在解决瘤负担和呼吸道阻塞方面可能存在局限性.
研究的目的:
- 评估支气管动脉化学栓塞 (BACE) 的临床应用和临床结果,用于耐火性中心肺癌和脱氧症患者.
主要方法:
- 在2012年1月至2021年12月期间接受BACE治疗的30名患者的回顾性病例系列.
- 评估卡诺夫斯基性能状况 (KPS),瘤反应 (RECIST),形脱缓解,以及生存率 (PFS,OS).
主要成果:
- 在BACE后的KPS分数显著改善 (82.0与68.3相比,P<0.001).
- 瘤反应:4个CR,16个PR,9个SD,1个PD. 八个病例显示有支气管再通道化和阿特莱克塔斯缓解.
- 中位数PFS为7.0个月和OS为10.0个月;一年生存率为84.0%.
结论:
- BACE是一种潜在的安全和有效的干预措施,用于耐火性中枢肺癌与atelectasis.
- 该程序证明了令人满意的瘤控制,阿特莱克塔斯缓解和改善生活质量.
- 需要进一步的调查来证实这些发现.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Flail Chest-II
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:


